Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes...

Tailwinds' Take: Fortress' value add is in finding underdeveloped drugs that have excellent scientific research and bringing them through the FDA process and to...

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell...

Tailwinds' Take: the many shots on goal under the FBIO umbrella is one of the most compelling aspects of the company. This is great...

Journey Medical Corporation Recaps 2019 Growth

Tailwinds' Take: Journey is growing rapidly as they execute on the overall strategy of FBIO; licensing low-risk products and bringing them to market. This...

What to Expect When Everyone’s Expecting (An Up Market)

What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical...

Tailwinds' Take: this deal demonstrates the effectiveness of FBIO's business model. They are accumulating a plethora of interesting drugs under their umbrella.  NEW YORK, Dec....
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.